DXM/BUP Antidepressant Shows No Link to Diabetes Risk

DXM/BUP Antidepressant and Diabetes Risk: New Findings

A recent study published on August 7, 2026, in OpenAlex has examined the potential metabolic side effects of the antidepressant combination dextromethorphan/bupropion (DXM/BUP). Utilizing data from the Food and Drug Administration's Adverse Event Reporting System (FAERS), the study found no significant association between DXM/BUP and an increased risk of diabetes mellitus or hyperglycemia. This finding is crucial for clinicians concerned about the metabolic side effects of antidepressants, particularly those treating Major Depressive Disorder (MDD) in adults.

Mechanism and Context of DXM/BUP

DXM/BUP is the first orally administered antidepressant approved by the United States Food and Drug Administration (FDA) that combines dextromethorphan, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion, a CYP2D6 inhibitor and antidepressant. Approved in August 2022 for MDD treatment, the combination has been under scrutiny due to concerns about potential metabolic side effects, a common issue with some psychotropic agents. The study's analysis used reporting odds ratios (RORs) to compare DXM/BUP with other agents, using acetaminophen as a reference comparator.

Policy and Research Implications

The findings of this study have significant implications for policy and clinical practice. By demonstrating no significant link between DXM/BUP and metabolic disorders, the research supports the continued use of this combination in treating MDD without added concern for diabetes risk. This can lead to more confident prescribing practices among clinicians, potentially increasing the adoption of DXM/BUP where appropriate. Furthermore, the study highlights the importance of pharmacovigilance data in assessing drug safety, encouraging ongoing monitoring and research in this area.

Risks and Unknowns in DXM/BUP Use

Despite the reassuring findings, there remain risks and unknowns associated with DXM/BUP use. The study's reliance on FAERS data, which is based on voluntary reporting, may not capture all adverse events, leading to potential underreporting. Additionally, the study's timeframe, from the drug's approval to April 2026, may not be sufficient to detect long-term metabolic effects. Clinicians should continue to monitor patients for any adverse reactions and consider individual patient risk factors when prescribing DXM/BUP.

Looking Forward: Future Research Directions

Moving forward, further research is needed to confirm these findings over a longer period and in more diverse populations. Longitudinal studies with larger sample sizes could provide more comprehensive insights into the long-term safety profile of DXM/BUP. Additionally, exploring the mechanisms by which DXM/BUP may interact with metabolic processes could uncover new therapeutic targets or potential side effects. As the field of psychedelic research evolves, continuous evaluation of drug safety will remain a priority to ensure patient well-being.